You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

 

Online download statistics by month:

Online download statistics by month: December 2019 to August 2025

AbstractFullPdf
Dec 2019110
Jan 202017174
Feb 202015156
Mar 202028284
Apr 202019196
May 2020434312
Jun 202046462
Jul 202034344
Aug 2020363615
Sep 2020555518
Oct 2020525245
Nov 2020616142
Dec 2020353422
Jan 2021606040
Feb 2021292916
Mar 2021707046
Apr 2021444435
May 2021484823
Jun 2021434321
Jul 2021343430
Aug 2021393914
Sep 2021464632
Oct 2021424238
Nov 2021313129
Dec 2021454547
Jan 2022262712
Feb 2022292918
Mar 2022474715
Apr 2022616112
May 2022414117
Jun 2022262614
Jul 202233338
Aug 2022393918
Sep 2022272718
Oct 2022313118
Nov 2022192221
Dec 2022404013
Jan 2023343410
Feb 202323248
Mar 2023454619
Apr 2023333510
May 202314149
Jun 202330305
Jul 2023191913
Aug 2023282811
Sep 202323239
Oct 2023414120
Nov 202329318
Dec 2023494920
Jan 2024949618
Feb 202421219
Mar 2024353517
Apr 2024262614
May 2024353615
Jun 2024343318
Jul 2024555527
Aug 2024242213
Sep 2024252517
Oct 2024252523
Nov 2024293015
Dec 2024434322
Jan 2025555530
Feb 2025242419
Mar 2025363618
Apr 2025565714
May 2025414160
Jun 202528288
Jul 2025220
Aug 2025210
Total245024601234